Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2011 - 2026)
Oramed Pharmaceuticals (ORMP) reported Income from Continuing Operations of 38310000.0 for Q1 2026, up 601.31% on a YoY basis from 5462645.45 in Q1 2025, and up 282.76% quarter-over-quarter from 10009000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals has reported Income from Continuing Operations for 15 years, with the latest figure at 38310000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 601.31% year-over-year to 38310000.0; the trailing twelve-month figure through Mar 2026 stood at 109968000.0 (up 488.87% YoY), and the FY2025 full-year result was 64016000.0, up 435.11% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 38310000.0, up from 10009000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 48389000.0 in Q3 2025, with the low at 19642000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 2619823.53 across 5 years, with a median of 3284000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 800.99% — and 2025, when it slumped 598.17%.
- Oramed Pharmaceuticals' Income from Continuing Operations stood at 12255000.0 in 2022, then surged by 208.49% to 13296000.0 in 2023, then slumped by 176.71% to 10199000.0 in 2024, then surged by 198.14% to 10009000.0 in 2025, then jumped by 282.76% to 38310000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 38310000.0 (Q1 2026), 10009000.0 (Q4 2025), and 48389000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Oramed Pharmaceuticals | 149.44 Mn | 131.27 Mn | - | 38.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.31 Mn |
| Dec 31, 2025 | 10.01 Mn |
| Sep 30, 2025 | 48.39 Mn |
| Jun 30, 2025 | 13.26 Mn |
| Mar 31, 2025 | -7.64 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Sep 30, 2024 | -19.64 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 13.30 Mn |
| Sep 30, 2023 | -3.28 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -5.21 Mn |
| Dec 31, 2022 | -12.26 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -11.42 Mn |
| Mar 31, 2022 | -11.25 Mn |
| Aug 31, 2021 | -22.99 Mn |
| Nov 30, 2019 | -2.45 Mn |
| Aug 31, 2019 | 14.06 Mn |